BACKGROUND: Reduction of E-cadherin in most common epithelial tumors relates to metastasis, which results from the silence of E-cadherin by CpG methylation. MATERIALS AND METHODS: We examined the E-cadherin expression by immunohistochemical staining and detected methylation by methylation-specific polymerase chain reaction (MSP) in 48 primary oral SCC tissues. RESULTS: The results showed that 41 out of 48 (85.4%) cancerous tissues and 16 out of 48 (33.3%) nearby non-cancerous tissues had CpG methylation on the promoter region of E-cadherin. In these non-cancerous tissues, 2 out of 16 (12.5%) had no methylation change in their paired cancerous part. Immunohistochemical study showed that a decreased expression pattern was found in the tissue which had CpG methylation on the promoter region, but an over expression island or aberrant expression was also frequently found in these cases. CONCLUSION: The methylation of E-cadherin in oral SCC may occur in the precancerous stage and the process is dynamic, which has no relationship with the aberrant expression of E-cadherin protein.
BACKGROUND: Reduction of E-cadherin in most common epithelial tumors relates to metastasis, which results from the silence of E-cadherin by CpG methylation. MATERIALS AND METHODS: We examined the E-cadherin expression by immunohistochemical staining and detected methylation by methylation-specific polymerase chain reaction (MSP) in 48 primary oral SCC tissues. RESULTS: The results showed that 41 out of 48 (85.4%) cancerous tissues and 16 out of 48 (33.3%) nearby non-cancerous tissues had CpG methylation on the promoter region of E-cadherin. In these non-cancerous tissues, 2 out of 16 (12.5%) had no methylation change in their paired cancerous part. Immunohistochemical study showed that a decreased expression pattern was found in the tissue which had CpG methylation on the promoter region, but an over expression island or aberrant expression was also frequently found in these cases. CONCLUSION: The methylation of E-cadherin in oral SCC may occur in the precancerous stage and the process is dynamic, which has no relationship with the aberrant expression of E-cadherin protein.
Authors: R J Shaw; T Liloglou; S N Rogers; J S Brown; E D Vaughan; D Lowe; J K Field; J M Risk Journal: Br J Cancer Date: 2006-02-27 Impact factor: 7.640
Authors: Chi T Viet; Gary Yu; Kesava Asam; Carissa M Thomas; Angela J Yoon; Yan Chen Wongworawat; Mina Haghighiabyaneh; Courtney A Kilkuts; Caitlyn M McGue; Marcus A Couey; Nicholas F Callahan; Coleen Doan; Paul C Walker; Khanh Nguyen; Stephanie C Kidd; Steve C Lee; Anupama Grandhi; Allen C Cheng; Ashish A Patel; Elizabeth Philipone; Olivia L Ricks; Clint T Allen; Bradley E Aouizerat Journal: Biomark Res Date: 2021-06-05
Authors: Tack Kune You; Kyoung Min Kim; Sang Jae Noh; Jun Sang Bae; Kyu Yun Jang; Myoung Ja Chung; Woo Sung Moon; Myoung Jae Kang; Dong Geun Lee; Ho Sung Park Journal: Korean J Pathol Date: 2012-08-23